719TiP SunRISe-1: Phase IIb study of TAR-200 in combination with cetrelimab (CET), TAR-200 alone, or CET alone in participants with high risk non-muscle invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guérin who are ineligible for or elected not to undergo radical cystectomy

2021 ◽  
Vol 32 ◽  
pp. S723-S724
Author(s):  
M.S. van der Heijden ◽  
C. Cutie ◽  
M. Acharya ◽  
K. Stromberg ◽  
X. Li ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Radical Cystectomy ◽  
Invasive Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer

2018 ◽  
Vol 102 (1) ◽  
pp. 60-68 ◽  
Author(s):  
Wojciech Krajewski ◽  
Romuald Zdrojowy ◽  
Janusz Dembowski ◽  
Sławomir Poletajew ◽  
Michał Wróbel ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Invasive Bladder Cancer ◽  
Optimal Timing ◽  
Bacillus Calmette Guerin ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure

2021 ◽  
Vol 15 (1) ◽  
pp. 33-38
Author(s):  
Govind Shantharam ◽  
Ali Amin ◽  
Jorge Pereira ◽  
Ohad Kott ◽  
Catrina Mueller-Leonhard ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Invasive Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document